AVITA Medical

VALENCIA, Calif. and MELBOURNE, Australia, Sept. 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced positive topline results from a pivotal randomized, controlled trial evaluating the safety and effectiveness of the RECELL System for repigmentation of stable vitiligo lesions.

The study compared repigmentation success rates, in a design where each patient randomly received RECELL treatment in one portion of depigmented area and treatment with the study control in another portion of depigmented area. The study control treatment was the standard of care narrowband ultraviolet-B phototherapy, which is typical first-line treatment for vitiligo. Repigmentation was evaluated 6 months after treatment by an expert central review committee (CRC).

The CRC reported the following:

Fifty-six percent (56%) of RECELL treatments (versus 12% of control treatments) resulted in repigmentation of more than 50% of the treated area

Thirty-six percent (36%) of RECELL treatments (versus 0% of control treatments) resulted in repigmentation of at least 80% of the treated area, establishing super-superiority for the primary endpoint (p<0.025)

RECELLs compelling safety profile to date is reflected in preliminary review of adverse events in this study.

These are the first results from a U.S. randomized, controlled trial of the RECELL System in treating patients with segmental and nonsegmental stable vitiligo and provide a foundation for communicating favorable clinical benefit in pursuit of FDA approval via submission of a PMA supplement for this indication later this year.

Vitiligo often has a severe impact on quality of life and is a therapeutic area within which there have been very limited treatment options. We are excited by our topline data, as we are now closer to our goal of providing patients with a durable, clinically meaningful, one-time treatment for repigmentation, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. RECELL has the potential to address the unmet medical need for an estimated 1.3 million people in the U.S. who suffer from stable vitiligo, and further, we envision a potential opportunity for RECELL as part of a multi-modal treatment plan for patients achieving stability with JAK inhibitor treatment.

Story continues

Repigmentation is challenging to manage and burdensome for patients with vitiligo, said Iltefat Hamzavi, MD, of Henry Ford Hospital (Detroit, MI), lead investigator of the trial. These are encouraging results that underscore the potential for RECELL to address repigmentation in patients with stable vitiligo in a rapid and sustained fashion which is distinct from existing therapies.

Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including up to 6.5 million Americans,ii with an estimated 1.3 million suffering from stable vitiligo. Vitiligo has a comparable psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iii, iv, v Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.vi

ABOUT AVITA MEDICAL, INC.AVITAMedical is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The RECELL System technology platform, approved by the FDA for the treatment of acute thermal burns in both adults and children, harnessesthe regenerative properties of a patients own skin to create Spray-On Skin cells. Delivered at the point-of-care, RECELL enables improved clinical outcomes and validated cost savings. RECELL is the catalyst of a new treatment paradigm and AVITA Medical is leveraging its proven and differentiated capabilities to develop first-in-class cellular therapies for multiple indications, including acute traumatic wounds and repigmentation of stable vitiligo lesions.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is approved for acute partial-thickness thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. In February 2022, the FDA reviewed and approved the PMA supplement for RECELL Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 15,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are approved under the RECELL System brand to promote skin healing in a wide range of applications including burns, acute traumatic wounds, vitiligo, and aesthetics. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe and has PMDA approval in Japan. To learn more, visitwww.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

U.S. MediaSam Brown, Inc.Christy CurranPhone +1-615-414-8668christycurran@sambrown.com

O.U.S. MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au

InvestorsWestwicke PartnersCaroline CornerPhone +1-415-202-5678 caroline.corner@westwicke.com

i Picardo et al. Vitiligo. Nature Reviews Disease Primers. 2015.ii John Harris, MD, PhD Presentation as part of Incyte Corporate presentation. (Harris, UMass, is a global leader in Vitiligo; AVITA collaborator). https://investor.incyte.com/static-files/01f77a1c-6351-4348-adc2-597e2bc1f42eSERTiii National Psoriasis Foundation Statistics, https://www.psoriasis.org/psoriasis-statistics/ Accessed 10/5/2020iv The burden of vitiligo: Patient characteristics associated with quality of life. Homan, et al. JAAD. 2009v Comparison of the Psychological Impacts of Asymptomatic and Symptomatic Cutaneous Diseases: Vitiligo and Atopic Dermatitis.Noh, et al. Annals of Derm. 2013vi Willingness-to-pay and quality of life in patients with vitiligo. Radtke, et al. BJD. 2009

See the original post here:
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System - Yahoo Finance

Life sciences company Carmell Therapeutics started September by taking the first steps toward going public: filing a draft registration statement with the US Securities and Exchange Commission for a public stock listing.

CEO and President Randy Hubbell told Technical.ly that taking the company public primes the Carmell Therapeutics products for commercialization. Currently in the clinical development stage, the South Side-based startup has investors, but no revenue. So when the company has finished with its clinical trials and been listed on the Nasdaq its aiming for Q4 2022 or early 2023 Hubbell says the company will be able to show the value of its products and positively impact future sales.

Why follow the 2021 steps of fellow Pittsburgh companies Duolingo, Stronghold Digital Mining, Aurora and Cognition Therapeutics and go public?

We believe that the better place to be is in the public markets where we can attract capital, because we look a lot like a biotech company, Hubbell said. Biotech companies have had success in the public markets by creating value for their investors by successfully advancing through the clinical regulatory pathway and bringing forth significant clinical data.

Randy Hubbell. (Courtesy photo)

The products Carmell Therapeutics would like to advance focus on regenerative medicine, including for tissue, hair, skin, bones after injury, disease or aging. Recently the company has completed Phase 2 of a study showing its Bone Healing Accelerant which has the ability to (as you might have guessed) accelerate and heal bone and soft tissue damage. The second product its been preparing is its Tissue Healing Accelerant which focuses on chronic wound healing and hair regrowth for individuals with alopecia.

All of those applications are very large total available markets, and all of them have significant unmet needs, Hubbell said. Our technology has promise of working to regrow those tissues because the base technology is very well understood and the science is very well known.

The Carnegie Mellon University spinout develops its technology by using allogeneic plasma, which contains significant growth factors and regenerative factors that are an important part of regrowing tissue. Hubbell explained that recently the company had obtained the Investigational New Drug clearance from the US Food and Drug Administration, meaning it has the green light to conduct clinical testing of the Bone Healing Accelerant. Additionally, the FDA has granted the companys technology an expedited review, a process meant to get important drugs to patients faster.

That suggests that they see that there is a significant unmet need without the necessary technology to address and they believe our technology would help meet that medical unmet need in tibia fractures, Hubbell said. What were doing is a big vision. It could fundamentally change the way tissue is healed and regrows after disease, injury and aging.

Carmell Therapeutics HQ. (Courtesy photo)

With plans to go public and clinical trials progressing, Hubbell said the company currently comprising 15 employees, nine of which are Pittsburgh based is set to expand by doubling its staff and possibly expanding its building to accommodate manufacturing when the time for commercialization comes. Still, even as the company grows larger with more researchers and finance staff, Hubbell insists Carmell Therapeutics is committed to continuing to call Pittsburgh home.

Were fully committed to Pittsburgh, were fully committed to the River Park Commons facility, the CEO said of Carmells HQ. We have no, no plans on leaving the Pittsburgh area or South Side.

Excerpt from:
Following some big FDA wins, Carmell Therapeutics plans to go public. Here's why - Technical.ly

Chicago, Sept. 13, 2022 (GLOBE NEWSWIRE) -- According to the new market research report "Cell Culture Media Market by Type(Serum-free (CHO, BHK, Vero Cell), Stem Cell, Chemically Defined, Classical, Specialty), Application(Biopharmaceutical (mAbs, Vaccine), Diagnostics, Tissue Engineering), End User(Pharma, Biotech) - Global Forecast to 2026", is projected to USD 10.3 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 16.0 % between 2021 and 2026.

Browse in-depth TOC on "Cell Culture Media Market"314 - Tables41 - Figures303 - Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=97468536

The growth of this market is majorly driven by the rising R&D spending in pharmaceutical companies, emerging cell culture technologies for cell-based vaccines, increasing demand for monoclonal antibodies, growth in stem cell research, the launch of new cell culture media by market players, and the growing focus on personalized medicine. On the other hand, expensive cell biology research products and ethical concerns regarding cell biology research are expected to hinder the growth of this market.

Based on type, the cell culture media market is segmented intoserum-free media, classical media & salts, stem cell culture media, specialty media, chemically defined media, and other cell culture media. In 2020, the serum-free media segment accounted for the largest share of the market. This can be attributed to the advantages of serum-free media over other types of media, including consistent performance, increased growth & productivity, better control over physiological responsiveness, and reduced risk of contamination by serum-borne adventitious agents in cell culture.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=97468536

Based on application, the cell culture media market is categorized into biopharmaceutical production, diagnostics, drug discovery & development, tissue engineering & regenerative medicine, and other applications. The biopharmaceutical production segment is further divided into monoclonal antibody production, vaccine production, and other therapeutic protein production. The tissue engineering & regenerative medicine segment is further divided into cell & gene therapy and other tissue engineering & regenerative medicine applications.The biopharmaceutical production segment is estimated to grow at the highest rate during the forecast period. The high growth of this segment is attributed to the commercial expansion of major pharmaceutical and biotechnology companies, the increasing demand for mAbs, and the growing regulatory approvals for the production of cell culture-based vaccines.

Based on end user, the cell culture media market is segmented into pharmaceutical & biotechnology companies, hospitals & diagnostic laboratories, research & academic institutes, and other end users (such as cell banks, CDMOs, and CROs). In 2020, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market. This end-user segment is also estimated to grow at the highest growth rate during the forecast period.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=97468536

Geographical Growth Scenario:

The global cell culture media market has been segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific market is estimated to register the highest CAGR during the forecast period. The growing geriatric population, favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian economies are the major factors contributing to the growth of the market in the Asia Pacific.

Key Players:

Key players in the cell culture media market include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), and Sartorius AG (Germany), Corning Incorporated (US).

Browse Adjacent Markets:Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025

Cell Culture Market by Product (Consumables (Media, Serum, Reagent, Vessels), Equipment (Bioreactor, Centrifuge, Incubator)), Application (Vaccines, mAbs, Diagnostics, Tissue Engineering), End User (Pharma, Biotech, Hospital) - Global Forecast to 2026

Read more from the original source:
Cell Culture Media Market worth $10.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire

During the projected period, the market is anticipated to grow as patient preferences shift from traditional medication distribution to the use of enhanced drug administration.

JERSEY CITY, N.J., Sept. 15, 2022 /PRNewswire/ -- Verified Market Research recently published a report, "Pharmaceutical Drug Delivery Market" By Route of Administration (Oral Drug Delivery, Injectable Drug Delivery), By Application (Infectious Diseases, Cancer), and By Geography.

According to an extensive study conducted by Verified Industry Research on the Pharmaceutical Drug Delivery Market, the market was valued at USD 1,403.2 Billion in 2021 and is projected to reach USD 2,583 Billion by 2030, growing at a CAGR of 6.6% from 2022 to 2030.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=7648

Browse in-depth TOC on "Pharmaceutical Drug Delivery Market"

202 - Pages126 Tables37 Figures

Global Pharmaceutical Drug Delivery Market Overview

The processes, formulations, manufacturing procedures, storage arrangements, and technologies utilized to deliver a pharmaceutical substance to its designated therapeutic location are referred to as drug delivery. To increase efficacy and safety, as well as patient convenience and compliance, principles relating to drug production, mode of administration, site-specific targeting, metabolism, and toxicity are applied.

Drug delivery uses a variety of excipients, medicine carriers, and medical devices to modify the pharmacokinetics and specificity of a drug. There is a greater focus on extending a drug's duration of action and bioavailability in order to improve therapeutic outcomes.

Drug delivery is a concept that is closely related to dose form and mode of administration; in fact, the latter is occasionally included in the definition. Despite the fact that the phrases drug delivery and route of administration are sometimes used interchangeably, they are two different ideas. The term "route of administration" refers to the way a medication takes to enter the body, even if "drug delivery" also includes the engineering of delivery systems and may comprise various dosage forms and devices.

Chronic illness incidence is on the rise, the biologics industry is expanding, and new innovative products are being introduced. Ocular inserts, insulin jets, wearables, and other medical devices are being used more often as a result of innovative product debuts that have raised user satisfaction and productivity. The global pharmaceutical delivery market is anticipated to increase as a result of significant investments made by manufacturers in identifying patient requirements and developing products that address those needs.

The Global pharmaceutical drug delivery market has been segmented by Verified Market Research by route of administration, under which the oral drug delivery segment is expected to lead the market. The infectious diseases segment leads the market by application.

Key Developments

Key Players

The major players in the market are Johnson & Johnson, Novartis International AG, F. Hoffmann-La Roche AG, Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Boehringer Ingelheim, Merck & Co., Inc., Sanofi, and AbbVie Inc.

Verified Market Research has segmented the Global Pharmaceutical Drug Delivery Market On the basis of Route of Administration, Application, and Geography.

Browse Related Reports:

Insulin Delivery Devices Market By Device Type (Pumps, Pen Needles), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By End-User (Hospitals, Clinics), By Geography, And Forecast

Oxygen Conservation Devices Market By Product (Reservoir Oxygen Delivery Devices, Electromechanical Pulsing Devices), By End-Use (Hospitals And Clinics, Long-Term Care Units), By Geography, And Forecast

Healthcare Nanotechnology (Nanomedicine) Market By Modality (Treatment, Diagnostics), By Indication (Clinical oncology, Infectious diseases), By Application (Drug Delivery, Regenerative medicine), By Geography, And Forecast

Transmucosal Drug Delivery Devices Market By Product (Buccal Route, Rectal Route, Nasal Route), By Application (Hospital, Residential) By Geography, And Forecast

Leading Drone Package Delivery Companies taking off for quick deliveries

Visualize Pharmaceutical Drug Delivery Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SME's offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact Us

Mr. Edwyne FernandesVerified Market ResearchUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll Free: +1 (800)-782-1768Email: [emailprotected]Web: https://www.verifiedmarketresearch.com/Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/1315349/Verified_Market_Research_Logo.jpg

SOURCE Verified Market Research

Read the original:
Pharmaceutical Drug Delivery Market is expected to generate a revenue of USD 2,583 Billion by 2030, Globally, at 6.6% CAGR: Verified Market Research -...

SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with $165 million in financing to build on the foundational insights of world-renowned leaders in mRNA and cell therapy, combining the power of cell therapy with the precision of genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications.

Capstans foundational precision in vivo engineering technology builds on research conducted in the laboratories of world-renowned mRNA and cell therapy scientists at the University of Pennsylvania.

Capstans funding includes a recently closed $102 million Series A financing led by Pfizer Ventures and joined by Leaps by Bayer, Eli Lilly and Company, Bristol Myers Squibb, Polaris Partners, Alexandria Venture Investments, and all existing investors, which follows a $63 million seed financing led by Novartis Venture Fund and OrbiMed and joined by RA Capital, and Vida Ventures in November 2021.

Advancing Breakthrough Therapies through Precision in vivo Engineering

The company plans to use the funds to further its mission of advancing the clinical promise of cell-based therapies by enabling precise in vivo engineering of cells with payloads necessary to benefit patients across multiple disease categories. Capstans modular platform leverages the biological and technological expertise of its founding scientists and includes proprietary targeted lipid nanoparticles (tLNP) technology, a suite of targeting moieties to mediate cell type-specific uptake, and disease-specific mRNA payloads aimed at directly engineering, or ablating pathogenic cells through in vivo generated CAR T cells.

Capstan is prioritizing programs based on the potential to transform clinical standards of care. The companys initial efforts will focus on developing first-in-class in vivo CAR therapies, with the goal to deliver treatments in an outpatient setting, for patients who have diseases for which there are no effective treatments. Capstan also plans to leverage its precision delivery and engineering technology to advance new therapies for certain monogenic blood disorders.

Visionary Team of Accomplished Executives Poised to Deliver a Transformational Approach

Capstan is also pleased to announce that Laura Shawver, Ph.D., has joined the company as President and Chief Executive Officer. Dr. Shawver brings more than 20 years of experience in executive leadership positions in oncology and other serious diseases to this role, most recently serving as CEO of Silverback Therapeutics and President and CEO of Synthorx.

Our ambition at Capstan is to invent new clinical paradigms through targeted in vivo reprogramming of cells, said Dr. Shawver. Our founding scientific and operational team is purpose-built to advance programs to the clinic that unite decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology. We are also fortunate to have a distinguished investor syndicate that understands the cell therapy landscape and recognizes the potential of this innovative approach. I am thrilled to lead this team as we work toward making this vision a reality for patients.

Laura is an exceptional leader with a well-established track record in drug development and passion for addressing unmet needs in oncology and other serious diseases, said Michael Baran, Ph.D., Partner, Pfizer Ventures. We are delighted to have someone of Lauras caliber captain this exciting next chapter for Capstan to help unlock the potential of this transformative approach for patients.

Dr. Shawver joins an accomplished leadership team of industry veterans who have been at the forefront of cell and gene therapy, including Adrian Bot, M.D., Ph.D., Chief Scientific Officer, formerly Global Head and Vice President of Translational Medicine at Kite, a Gilead Company and previously Chief Scientific Officer at Kite Pharma; and Priya Karmali, Ph.D., Chief Technology Officer, who has over two decades of experience in the field of lipid nanoparticle mediated nucleic acid delivery technologies.

Building on Pioneering Work of World-Renowned Scientific Founders

Capstan builds on a deep history of collaborative research in mRNA-enabled and CAR-based medicines by our incredible group of scientific founders, said Christian Homsy, M.D., MBA, Capstans founding CEO. The company was established to deliver on the promise of cell-based medicines, and with Laura at the helm, is well-positioned to make rapid progress towards clinical evaluation.

The companys scientific founders include several of the experts from the University of Pennsylvania who authored two landmark studies establishing preclinical proof-of-concept for non-viral, in vivo CAR-T therapy that Capstan plans to develop and advance toward the clinic. A 2019 Nature publication demonstrated the preclinical use of ex vivo CAR-T cell therapy against FAP, a fibrosis-related target. A follow-on study published in Science earlier this year built on these earlier results and demonstrated the production of functional CAR-T cells in vivo in a mouse model following a single IV administration of an mRNA encoding an anti-FAP CAR packaged in CD5-targeted-LNPs. The scientific founders span diverse areas of research expertise:

Capstan is uniting several recent life science technological advances in a manner that can hopefully unlock the potential of these technologies to develop new medicines for patients across a wider range of diseases, said Drew Weissman, M.D., Ph.D., Co-Founder of Capstan, who serves as the Roberts Family Professor in Vaccine Research and Director of the Penn Institute for RNA Innovation in the Perelman School of Medicine at the University of Pennsylvania, and co-recipient of the 2021 Lasker-DeBakey Clinical Medical Research Award.

Research conducted at Penn demonstrates the tremendous promise of harnessing mRNA and targeted LNP delivery to train a patients body to make CAR-T cells in vivo, potentially creating new treatment options, said Jonathan Epstein, M.D., Chief Scientific Officer at Penns Perelman School of Medicine. We believe this approach has the potential to make an important impact not only in oncology, but also in fibrosis and many other diseases. My fellow scientific co-founders and I all look forward to actively partnering with Capstan in our collaborative effort to develop medicines that may benefit patients around the world.

About Capstan (www.capstantx.com)

Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need. The core technology comprises targeted Lipid Nanoparticles (tLNPs) to enable engineering or ablation of pathogenic cells in the body. The company is combining the power of cell therapy with the precision of genetic medicines to develop new treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. The Company is co-founded by pioneers in the field of CAR-based immunotherapy, nucleic acid drug delivery, tLNPs, and regenerative medicine, including experienced industry leaders, as well as academic faculty members from the University of Pennsylvania. Capstan has a bicoastal presence with operations in San Diego, CA and Philadelphia, PA. For more information, please visit http://www.capstantx.com and follow us on LinkedIn.

University of Pennsylvania Financial Disclosure: The laboratories of Drs. Epstein, Weissman, Pur, Albelda and June have received, or may receive in the future, sponsored research funding from Capstan. Penn, and Drs. Weissman, June, Levine, Epstein, Pur, Albelda, Parhiz and Aghajanian each own equity interests in Capstan. Penn and Drs. Weissman, June, Levine, Epstein, Pur, Albelda, Parhiz and Aghajanian have either received, or may receive in the future, license-related financial consideration related to the licensing of certain Penn intellectual property to Capstan. In their capacity as Penn faculty, Drs. Weissman, Albelda, June and Levine also have existing sponsored research and founding relationships with other commercial entities focused on the research and development of mRNA, LNP, cell therapy or immunotherapy technologies.

Read more:
Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business Wire

DALLAS Sept. 09, 2022 Childrens Health,one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, today announced that Childrens Health will initiate and create an approximately 100-bed inpatient unit at the new State Psychiatric Hospital for children and adolescents. The adult hospital is being developed through a partnership between UTSouthwestern Medical Center and the Texas Health and Human Services Commission (HHSC). The pediatric unit is in addition to 200 adult beds at the new state hospital, which is currently in the planning stages of design and construction and expected to open in fall 2025 with the pediatric addition scheduled to open in early 2026.

This donation is a key part of our comprehensive strategy and ongoing commitment to expand access to pediatric and adolescent behavioral health services in North Texas, said Lindsey Tyra, Executive Vice President and Chief Strategy Officer at Childrens Health. We know that addressing this growing pediatric mental health crisis requires a concerted, coordinated response from resources and experts across our community. In collaboration with UTSouthwestern through our joint pediatric enterprise, we are building a sweeping and forward-looking approach to this escalating problem that will also be part of a larger statewide system.

According to the Childrens Health 2021 Beyond ABC Report, an estimated 133,375 North Texas children suffer from an emotional disturbance or addictive disorder, and in 2020 alone, there was a 24% increase in mental health-related Emergency Room visits for children ages 5 to 11. By supporting the expansion of inpatient pediatric psychiatric services at the new state hospital, more North Texas children and adolescents through age 17 with complex mental health needs will have access to behavioral health services when they need it most.

Hicham Ibrahim, M.D.

Our goal is to build a state-of-the-art facility that meets the needs of the communities we serve, says Dr. Hicham Ibrahim, Professor of Psychiatry and Associate Vice President and Chief Medical Officer, Ambulatory Services at UTSouthwestern. This donation gives us the opportunity to better address the mental health crisis affecting pediatric patients in our region and provide them with the specialized care they deserve.

This hospital will save lives, and with this donation, thatll include the lives of children as well, said Scott Schalchlin, Deputy Executive Commissioner for the HHSC Health and Specialty Care System. By expanding access to children and adolescents, were helping to address a truly critical need in our communities: taking care of the mental and physical health of our young people.

For updates on the hospitals progress and additional information on how Childrens Health is working with UTSouthwestern and the Texas Health and Human Services Commission, visit State Hospital Construction Projects.

About UTSouthwestern Medical Center

UTSouthwestern, one of the nations premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 26 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,900 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in more than 80 specialtiesto more than 100,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 4 million outpatient visits a year.

About Childrens Health

Childrens Healthis committed to making life better for children. As one of the largest and most prestigious pediatric health care providers in the country and the leading pediatric health care system in North Texas, Childrens Health cares for children through more than 750,000 patient visits annually. The Childrens Health system includes its flagship hospital, Childrens Medical Center Dallas, as well as Childrens Medical Center Plano, the Childrens Health Care Network, specialty centers, rehabilitation facilities and physician services. Childrens Medical Center Dallas continues to be the only North Texas hospital to be ranked in 10 out of 10 pediatric specialties byU.S. News & World Report. Through its academic affiliation with UTSouthwestern Medical Center, Childrens Health is a leader in life-changing treatments, innovative technology and ground-breaking research. This affiliation led to establishing the Childrens Medical Center Research Institute in 2011, committed to pursuing research in regenerative medicine, cancer biology and metabolism. For more information, follow Childrens Health onFacebook,Twitter,Instagram LinkedInYouTube, or visitChildrens.com.

About Texas Health and Human Services

The Texas Health and Human Services Commission owns or operates10 state hospitals, one residential treatment center and 13 state supported living centers across the state. State hospitals provide inpatient psychiatric services to adults, children and adolescents, and state supported living centers serve individuals with intellectual or developmental disabilities. HHSC is also working to serve the growing needs of Texans by modernizing or expanding state hospitals throughout Texas and building a new hospital in Dallas.

Read more:
Children's Health will fund pediatric unit at the Texas Health and Human Services Commission UT Southwestern Medical Center psychiatric hospital - UT...

NEWARK, Del, Sept. 14, 2022 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global demand for cell line development market to increase at a CAGR of 5% during the forecast period between 2022 and 2032, reaching a total of US$ 7.66 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%.

The reasons for surge in the market include the increasing demand for regenerative medicine, shifting in focus towards advanced oncology research and rising demand for biologically derived pharmaceuticals. The advancements in culture technologies are expected to significantly impact the growth of the cell line development market through the forecast period. Moreover, the use of monoclonal antibodies as therapeutic agents to treat different types of diseased cells has invoked prospects of growth of the cell line development market.

Stable cell lines are used in various applications, such as drug screening, gene functional studies and biologics production. Increasing demand for monoclonal antibodies and other biological products will continue pushing sales in the cell line development market.

Request a Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7566

Key Takeaways from the Market Study

Compared to the existing mammalian expression systems, human cell lines possess the ability to produce proteins analogous to naturally synthesized proteins in the human body. This property is advantageous for the advancement in protein therapeutics, and acts as a driver for the growth of the biopharmaceutical industry. says an analyst at FMI.

Market Competition

Key players in the cell line development market are Thermo Fischer Scientific, Inc., GE Healthcare, Merck KGaA, Lonza (Sartorius Stedim Biotech S.A.), Danaher, Corning Incorporated. WuXi Biologics, Selexis SA and American Type Culture Collection (ATCC).

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-7566

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global cell line development market, presenting historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of product type (Reagent and Media, Equipment and Accessories and consumables), source type (Mammalian cell line and Non-mammalian cell line), cell lines (Recombinant, Hybridomas, Continuous and Primary cell lines) & region.

About the Healthcare Domain at Future Market Insights

The healthcare domain team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.

Table of Content

1. Executive Summary

1.1. Market Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Global Cell Line Development Market Opportunity Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

Get detailed TOC @ https://www.futuremarketinsights.com/toc/rep-gb-7566

Have a Look at Related Research Reports of Healthcare

Cell Therapy Systems Market Size covering sales outlook, demand forecast & up-to-date key trends

Cell Harvesting Systems Market Demand witnessed substantial growth owing to equipment efficacy and accuracy during stem cells harvest

Cell Culture Incubator Market Share is expected to be valued atUS$ 2,189.7 Millionin 2022, and is projected to reachUS$ 4,347.9 Millionby 2032

Cell Culture Media Bags Market Forecast is projected to increase from a valuation of US$ 1.18 Bn in 2022 to US$ 2.67 by the end of 2030

Lung Cancer Therapeutics Market Forecast: The global lung cancer therapeutics market share is projected to reach US$ 48,725.9 Mn by 2026, exhibiting a CAGR of 13.4% in the forecast period

ABOUT FUTURE MARKET INSIGHTS, INC.

Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5),we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.

Contact Us:

Future Market Insights Inc.Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, USAT: +1-845-579-5705For Sales Enquiries: sales@futuremarketinsights.comBrowse Latest Market Reports: https://www.futuremarketinsights.com/reports

Read the original:
Cell Line Development Market Projected to Experience a CAGR of 5% from 2022 to 2032, value worth US$ 7.66 Billion | Future Market Insights, Inc. -...

image:From left to right, Alba Elas-Tersa, Eduardo Soriano, Yasmina Manso and Marta Pascual, from the Department of Cell Biology, Physiology and Immunology of the Faculty of Biology and the Institute of Neurosciences (UBNeuro) of the UB, and the CIBERNED. view more

Credit: UNIVERSITY OF BARCELONA

The correct development of the brain cortex is an essential process for the acquisition of correct cognitive skills. Reelin, a key extracellular protein in neuronal migration and synaptic plasticity, is determinant in this process. For this reason, the dysfunction genetic or at an expression level of this protein is involved in neurodevelopmental pathologies such as lissencephalies, epilepsy or some psychiatric disorders, particularly autism, schizophrenia and bipolar disorder or neurodegenerative diseases.

Now, an article published in the journal Proceedings of the National Academy of Sciences (PNAS) reveals the decisive role of reelin expressed by the Cajal-Retzius pioneer neurons (CR) or cortical GABAergic neurons in the process of corticogenesis and neuronal migration. The study was led by Professor Eduardo Soriano, from the Department of Cell Biology, Physiology and Immunology of the Faculty of Biology and the Institute of Neurosciences (UBNeuro) of the University of Barcelona, and the Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), and its first authors are the researchers Alba Vlchez and Yasmina Manso (UB-UBNeuro-CIBERNED).

The study is based on the analysis of genetically modified mice to inactivate the reelin gene in pioneer CR neurons and cortical GABAergic interneurons. While CR cells play an essential role at early stages, the study stresses the fundamental role of the GABAergic interneuron-derived reelin in late neuronal migration, states Professor Eduardo Soriano.

A new model for reelin protein action

The team also described the existence of transient migratory deficits in some neuronal populations, a process that indicates that reelin expressed by any other of the neuronal populations is sufficient to reverse and compensate for some effects in cortical lamination in the brain. Based on this study, the authors present a new model of action for reelin, in the development of the cerebral cortex based on the cooperation and the spatial, cellular and sequential specific expression of this key protein.

Several neuropsychiatric disorders are linked to alterations in neuronal migration and reelin deficits in interneurons. Thus, this study can provide a better understanding of the mechanisms associated with human brain disorders related to reelin deficits associated with migration alteration, concludes the research team.

Among the coauthors of the study are Marta Pascual and Alba Elas-Tersa (UB-UBNeuro-CIBERNED); Vctor Borrell and Adrin Crdenas, from the Institute of Neurosciences (CSIC-Miguel Hernndez University); Manuel lvarez-Dolado and Magdalena Martnez-Losa, from the Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), and Angus C. Nairn, from Yale University (United States).

Proceedings of the National Academy of Sciences

Experimental study

Animals

Specific contribution of Reelin expressed by CajalRetzius cells or GABAergic interneurons to cortical lamination

6-Sep-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
UB researchers identify new model of cerebral cortex development linked to reelin protein expression - EurekAlert

Dr. Julie Russak, Board-Certified Dermatologist

NEW YORK (PRWEB) September 12, 2022

Julie E. Russak, M.D., FAAD., is a Board Certified Dermatologist, Founder of Russak Dermatology Clinic in Manhattan and specializes in general and cosmetic dermatology, regenerative aesthetic medicine, skin cancer and dermatologic surgery. Dr. Russak has received numerous honors and recognition of her clinical excellence, including being selected as a New York Super Doctor by New York Times Magazine.

An Integrative Approach to Aesthetic Medicine and Metabolic Aging on the Cellular LevelThe new physician and nutritionist-led program utilizes a 360 approach to aesthetics and longevity, designed to empower patients with the clinical data, tools and treatments to reverse the signs of aging and feel their best. The program was designed for patients who want to receive a custom plan on how to approach anti-aging and wellness together.- Dr. Julie Russak

In-house Board Certified Holistic Nutritionist & Celebrity Health Coach, Jennifer Hanway, alongside Dr. Russak, leads all patients through their highly-personalized testing analysis and develops customized nutrition, supplement, lifestyle and aesthetic treatment plans. Jennifers deep knowledge of hormonal imbalances, gut health and body composition informs her holistic approach.

Aging well is the mission of the program, and that requires more than skin deep procedures. We have the ability to reprogram gene expression to increase our healthspan, while resetting our cells to a more youthful state. Benefits of the program include slowing premature aging internally and externally, healthy skin and hair, hormone and metabolism optimization, weight loss, increased lean muscle mass, increased energy levels and mental clarity. - Jennifer Hanway.

Russak Dermatology Clinic works with leading integrative laboratories, specializing in epigenetic and functional testing including biological age, food intolerance, gut health, micronutrient and hormone panels. Hormones tell your tissues and organs what to do. A slight imbalance can cause fatigue, anxiety, acne, hair loss, weight change and more. Hormone health is a critical pillar of the program. -Jennifer Hanway.

A Regenerative ResetDr. Russaks Regenerative Aesthetics menu was designed to go hand-in-hand with the program. It includes therapies such as exosomes, stem cell facelift technology, platelet rich plasma (PRP), IV drips and bio-stimulatory injectables. The clinic carries clinical-grade skincare and nutraceuticals that boost the body's natural regenerative responses and have secured brand partnerships available to their patients, including health-expert designed, organic meal delivery service, Daily Dose and integrative supplement brand, Nutrafol.

Russak Dermatology Clinic ExpansionThe newly expanded aesthetic center will house the Anti-Aging Wellness Program and regenerative aesthetics offerings. The mission of the newly expanded space is to guide patients on how to harness the regenerative power of their own body. Think of your skins health, but elevated and enhanced through integrative and cutting-edge aesthetic treatments that address your bodys total wellness, inside and out.

About Dr. Julie RussakJulie E. Russak, M.D., FAAD., is a Board Certified Dermatologist and Founder of Russak Dermatology Clinic. Dr. Russak serves as Faculty at Mount Sinai Hospital, where she teaches dermatology residents and medical students. Dr. Russak has distinguished herself in the medical community through her clinical research, scientific presentations, publications and aesthetic approach. She attends anti-aging, aesthetic and regenerative medical conferences around the world to incorporate advancements in these fields into her practice. Some notable conferences include the Aesthetic & Anti-Aging Medicine World Congress and the Annual Mount Sinai Winter Symposium Advances in Medical and Surgical Dermatology".

Dr. Russak is frequently sought out by beauty editors and industry outlets as an expert contributor, including Good Morning America, NewBeauty, Cosmopolitan, Forbes, and Marie Claire. Dr. Russak serves as a consulting Dermatologist and formulator to clean skincare brand, Covey.

For all marketing and media inquiries, please contact Gabrielle@RussakDermatology.com. Learn more at http://www.russakplus.com and IG: @russakderm

Share article on social media or email:

Follow this link:
NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S. - PR Web